Nanohale AG (ETR:FYB) | WebDisclosure

PRESS RELEASE

published on 10/01/2024 at 17:06, 1 year 7 months ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH releases an update on Formycon AG, with analyst Simon Scholes reiterating a BUY rating and raising the price target from EUR 80 to EUR 82. The approval of the biosimilar FYB202 in the EU and US contributes to the positive outlook on Formycon's market share prospects

Investment Recommendation Formycon AG First Berlin Equity Research GmbH FYB202 Approval Biosimilar Market
BRIEF

published on 09/30/2024 at 07:35, 1 year 7 months ago

Formycon and Fresenius Kabi Receive FDA Approval for Biosimilar Otulfi

FDA Approval Biosimilar Formycon Fresenius Kabi Otulfi
BRIEF

published on 09/30/2024 at 07:35, 1 year 7 months ago

Formycon et Fresenius Kabi reçoivent l'approbation de la FDA pour le biosimilaire Otulfi

Approbation De La FDA Formycon Fresenius Kabi Biosimilaire Otulfi
PRESS RELEASE

published on 09/30/2024 at 07:30, 1 year 7 months ago

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for FYB202/OtulfiTM (ustekinumab-aauz) to treat several conditions including Crohn’s disease and psoriasis, expanding biosimilar market presence

FDA Approval Biosimilar Formycon Fresenius Kabi Ustekinumab
BRIEF

published on 09/27/2024 at 22:01, 1 year 7 months ago

FDA Grants Approval for Stelara® Biosimilar FYB202/OtulfiTM

FDA Approval Pharmaceutical Formycon AG Biosimilar Stelara®
BRIEF

published on 09/27/2024 at 22:01, 1 year 7 months ago

La FDA approuve le biosimilaire Stelara® FYB202/OtulfiTM

Formycon AG Approbation De La FDA Pharmaceutique Biosimilaire Stelara®
PRESS RELEASE

published on 09/27/2024 at 21:56, 1 year 7 months ago

EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
FDA grants approval for Stelara Biosimilar FYB202/Otulfi (ustekinumab-aauz) by Formycon AG. Approval based on comprehensive data evaluation. Contact: Sabrina Mueller, Formycon AG

FDA Approval Formycon AG FYB202 Stelara Biosimilar Sabrina Mueller
BRIEF

published on 09/27/2024 at 09:05, 1 year 7 months ago

European Commission Approves Formycon and Fresenius Kabi's Biosimilar FYB202/Otulfi®

European Commission Formycon Fresenius Kabi FYB202 Ustekinumab
BRIEF

published on 09/27/2024 at 09:05, 1 year 7 months ago

La Commission européenne approuve le biosimilaire FYB202/Otulfi® de Formycon et Fresenius Kabi

Formycon Fresenius Kabi FYB202 Ustekinumab Commission Européenne
PRESS RELEASE

published on 09/27/2024 at 09:00, 1 year 7 months ago

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Formycon and Fresenius Kabi secure European Commission approval for FYB202/Otulfi® (ustekinumab) to treat inflammatory diseases, expanding biosimilar portfolio

Biosimilar Formycon Fresenius Kabi Ustekinumab European Commission Approval

Published on 05/14/2026 at 15:10, 1 hour 4 minutes ago

Banyan Provides Summary of 2025 Diamond Drill Program for the Flagship AurMac Project, Yukon, Canada
Published on 05/14/2026 at 15:00, 1 hour 14 minutes ago

Karbon-X Explores Clean Cooking and Fish Smoking Climate Initiative Concept in Senegal
Published on 05/14/2026 at 15:00, 1 hour 14 minutes ago

ACCESS Newswire Celebrates PRSSA Bateman Competition Success and the Next Generation of Communications Leaders
Published on 05/14/2026 at 14:50, 1 hour 24 minutes ago

Germany's BGR Assesses NextSource Materials' Molo Graphite Mine as Part of Federal Critical Minerals Study
Published on 05/14/2026 at 14:30, 1 hour 44 minutes ago

Boron One Holdings Inc. Completes Its Jarandol Basin Exploration Program for 2026

View all ACCESSWIRE

Published on 05/14/2026 at 14:55, 1 hour 19 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 05/14/2026 at 14:54, 1 hour 19 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 05/14/2026 at 14:53, 1 hour 20 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 05/14/2026 at 14:53, 1 hour 21 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 05/14/2026 at 14:52, 1 hour 21 minutes ago

Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc

View all EQS

Published on 05/14/2026 at 09:03, 7 hours 11 minutes ago

Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 22 hours 12 minutes ago

ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
Published on 05/13/2026 at 18:00, 22 hours 14 minutes ago

DDV monthly statement at April 30 2026
Published on 05/13/2026 at 18:00, 22 hours 14 minutes ago

DDV declaration au 30 avril 2026
Published on 05/13/2026 at 18:00, 22 hours 14 minutes ago

ALTAREIT - Assemblée Générale Mixte du 4 juin 2026 - Modalités de mise à disposition des documents préparatoires

View all LES ECHOS COMFI WIRE

News